IVIg in the treatment of patients with factor VIII inhibitors
Ten years ago M. Kazatchkine, U. Nydegger, and Y. Sultan decided to treat patients with acquired hemophilia using intravenous immunoglobulins (IVIg). This was during a meeting in Denmark about autoimmune diseases and IVIg. In 1983, several authors had reported on the efficacy of IVIg in autoimmune diseases such as idiopathic thrombocytopenic purpura in children1,2 and adults,3 immune neutropenia,2,4 and red cell aplasia.5 Autoantibodies to factor VIII (F.VIII) occurring in either otherwise healthy patients or during the course of a more characterized immune disorder such as disseminated lupus erythematosus (DUE) and rheumatoid polyarthritis seemed to be good models. One major reason is that the neutralizing capacity of autoantibodies to F.VIII is easily and reproducibly quantified using the Bethesda assay, while this is not the case in most of the autoimmune diseases mentioned above.
KeywordsFactor Viii Idiopathic Thrombocytopenic Purpura Inhibitor Titer Factor Viii Inhibitor High Dose Intravenous Immunoglobulin
Unable to display preview. Download preview PDF.
- 1.P. Imbach, S. Barandun, V. d’Apuzzo et al.. High dose intravenous gammaglobulin, for idiopathic thrombocytopenic purpura in childhood. Lancet i: 1228 (1981).Google Scholar
- 3.R.E. Schmidt, U. Budde, G. Schafer et al. High dose intravenous immunoglobulin for idiopathic thrombocytopenic purpura. Lancet ii: 475 (1981).Google Scholar
- 6.Y. Sultan, M.D. Kazatchkine, P. Maisonneuve, U.E. Nydegger, Anti-idiotypic suppression of autoantibodies to factor VIII (anti-haemophilic factor) by high-dose intravenous gammaglobulin. Lancet ii: 765 (1984).Google Scholar
- 9.R. Zimmerman, B. Kommereil, J. Herenberg, W. Eich, K. Rother, KL. SchimpfGoogle Scholar
- 10.Intravenous IgG for patients with spontaneous inhibitor to factor VIII, Lancet i:273 (1985).Google Scholar